These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 17577497

  • 1. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S.
    J Clin Oncol; 2008 Oct 01; 26(28):4634-8. PubMed ID: 18574158
    [Abstract] [Full Text] [Related]

  • 6. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 7. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M.
    Clin Calcium; 2007 Feb 01; 17(2):241-8. PubMed ID: 17272882
    [Abstract] [Full Text] [Related]

  • 8. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.
    Ann N Y Acad Sci; 2011 Feb 01; 1218():47-54. PubMed ID: 20946574
    [Abstract] [Full Text] [Related]

  • 9. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May 01; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 10. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T.
    J Craniomaxillofac Surg; 2008 Mar 01; 36(2):95-103. PubMed ID: 18234504
    [Abstract] [Full Text] [Related]

  • 11. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug 01; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?
    Zavras AI, Zhu S.
    J Oral Maxillofac Surg; 2006 Jun 01; 64(6):917-23. PubMed ID: 16713806
    [Abstract] [Full Text] [Related]

  • 13. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.
    Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Piantadosi CA.
    J Oral Maxillofac Surg; 2007 Jul 01; 65(7):1321-7. PubMed ID: 17577496
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R, Wilson T, Grbic JT.
    Dent Today; 2006 Aug 01; 25(8):52, 54-7. PubMed ID: 16925161
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.
    J Clin Oncol; 2009 Nov 10; 27(32):5356-62. PubMed ID: 19805682
    [Abstract] [Full Text] [Related]

  • 16. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T, Cheng A, Stein B, Goss A.
    J Oral Maxillofac Surg; 2007 Mar 10; 65(3):415-23. PubMed ID: 17307586
    [Abstract] [Full Text] [Related]

  • 17. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS, McNulty RM, Kraut EH, Turowski RC.
    Cancer Invest; 2009 Dec 10; 27(10):984-8. PubMed ID: 19909013
    [Abstract] [Full Text] [Related]

  • 18. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB.
    J Oral Maxillofac Surg; 2009 May 10; 67(5 Suppl):44-52. PubMed ID: 19371814
    [Abstract] [Full Text] [Related]

  • 19. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
    Van Poznak C.
    Cancer Invest; 2006 Feb 10; 24(1):110-2. PubMed ID: 16467002
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N.
    J Oral Maxillofac Surg; 2009 Apr 10; 67(4):850-5. PubMed ID: 19304045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.